# Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531

> **NCT00479349** · PHASE1 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 32 (estimated)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** SAM-531

## Key facts

- **NCT ID:** NCT00479349
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2009-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00479349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00479349, "Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT00479349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*